Skip to main content


  • strict warning: Non-static method view::load() should not be called statically in /home/stable/domains/ on line 842.
  • strict warning: Declaration of content_handler_field::options() should be compatible with views_object::options() in /home/stable/domains/ on line 208.
  • strict warning: Declaration of views_handler_filter::options_validate() should be compatible with views_handler::options_validate($form, &$form_state) in /home/stable/domains/ on line 589.
  • strict warning: Declaration of views_handler_filter::options_submit() should be compatible with views_handler::options_submit($form, &$form_state) in /home/stable/domains/ on line 589.
  • strict warning: Declaration of views_handler_filter_boolean_operator::value_validate() should be compatible with views_handler_filter::value_validate($form, &$form_state) in /home/stable/domains/ on line 149.
  • strict warning: Declaration of views_plugin_style_default::options() should be compatible with views_object::options() in /home/stable/domains/ on line 25.
  • strict warning: Declaration of views_plugin_row::options_validate() should be compatible with views_plugin::options_validate(&$form, &$form_state) in /home/stable/domains/ on line 135.
  • strict warning: Declaration of views_plugin_row::options_submit() should be compatible with views_plugin::options_submit(&$form, &$form_state) in /home/stable/domains/ on line 135.

World First!
PapilloCheck From Greiner Bio-One

DNA chip improves early diagnosis of cervical cancer.

For women with cervical cancer, an early diagnosis can be life saving. If the cervical carcinomas are diagnosed early enough, the cancer is practically 100% curable. If the cancer is not found in time, the disease can become fatal: with almost 471,000 new cases throughout the world, this is the second most common type of cancer. 233,000 women die worldwide, 30,000 in Europe.

In spite of routine early diagnosis checks carried out in Austria and paid for by compulsory health insurance, Austria still has some of the highest rates of cervical cancer incidences and deaths in Europe. A reason for this could be that the Pap smear test checks for degenerated cells, but not for one of the causes of the illness, the human papilloma virus (HPV), which can be detected long before cancer develops.


HPV Risk and Early Diagnosis

The risk of infection is high. HPV infections are amongst the most frequent sexually transmitted diseases. Up to 75% of all humans are infected at some point in their life with HPV. The risk potential for becoming ill depends on the type of papilloma virus. This is where the Greiner Bio-One DNA-Chip PapilloCheck comes in. With PapilloCheck, 24 different types of HPV can be detected. It is necessary to differentiate between HPV types with a high risk (HR) or low risk (LR) of triggering cervical cancer. LR-HPV types can cause, amongst other things, benign verrucous changes in the genital mucosa, i.e. condylomata.


Precise Findings on DNA Basis

Due to the reliable genotyping of HPV types, PapilloCheck provides better risk analysis for the patient. In addition, the integrated control system guarantees the quality of the cervical smear. This can sometimes be decisive, if the specimen has not been collected correctly by the doctor, as can often be the case. Greiner Bio-One already has the official in-vitro diagnostics (IVD) certification for PapilloCheck in the European Union.

Detection of the human papilloma virus means that the trigger for cervical cancer can be diagnosed early, thus allowing the possibility of very good chances of recovery (up to 100%) for women with cervical cancer.

Download PDF

Download PDF

Download PDF

Download PDF